Up-Regulation of miR-21, miR-25, miR-93, and miR-106b in Gastric Cancer

Abstract

Background: Differential expression profile of microRNAs (miRNAs) could be a diagnosis signature for monitoring gastric cancer (GC) progression. In this study, we focus on the comparison of expression levels of miR-21, miR-25, miR-93, miR-106b, and miR-375 during the sequential pattern of GC development, including normal gastric, gastric dysplasia, and GC sample.

Methods: We used SYBR Green-based quantitative-PCR to quantify miRNAs expression.

Results: Our analysis revealed the increased expression levels of miR-21 (p = 0.034), miR-25 (p = 0.0003), miR-93 (p = 0.0406), and miR-106b (p = 0.023) in GC samples. In addition, GC patients with positive lymph node metastasis showed the up-regulation of miR-25, miR-93, and miR-106b (p < 0.05).

Conclusion: Our findings suggested that the expression of miR-21, miR-25, miR-93, and miR-106b altered in GC, and some of them may be further investigated as biomarkers for GC early detection and prognosis prediction.

Keywords: Biomarkers; microRNAs; Stomach cancer.

Fig. 1

Relative expression (2^-ΔΔCt) of miR-21 (A), miR-25 (B), miR-93 (C), miR-106b (D), and miR-375 (E) in the studied samples. ^*, ^**, ^*** indicate p ≤ 0.05, p ≤ 0.01, and p ≤ 0.001, respectively.

Fig. 2

ROC curve analysis using different miRNAs for discriminating GC from normal tissue. ROC curves were constructed to show the specificity and sensitivity of miR-21 (A), miR-25 (B), miR-93 (C), and miR-106b (D).